N/A
Completed N=104
Start Treatment and Recovery for Opioid Use Disorder
Opioid Use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Source: ClinicalTrials.gov NCT04505540 ↗
Enrolled (actual)
104
Serious AEs
0.0%
Results posted
Dec 2023
Primary outcomePrimary: Number of Participants With Self-reported Treatment Retention — 51 Participants
Summary
The purpose of this study is 1) to evaluate whether emergency department-initiated medically assisted treatment with Buprenorphine/Naloxone in patients presenting with opioid use disorder will produce positive outcomes at 1 week, 3 months and 6 months after treatment initiation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Self-reported Treatment Retention |
51 | — |
| SECONDARY Number of Participants With Illicit Opioid Use |
1 | — |
Eligibility Criteria
Inclusion Criteria
- Patient at Emergency Department
- Diagnosis opioid use disorder according to criteria Diagnostic and Statistical Manual (DSM) 5
Exclusion Criteria
- Participating in alternate treatment program for opioid use disorder
- Prisoner
- Inability to communicate
- Psychosis
- Suicidality
- History of Buprenorphine injection
- Critical Illness
Data sourced from ClinicalTrials.gov (NCT04505540). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.